Day 213: DVAX Thumbs Up

Mother's Little Helper portfolio was UP today +$2,799.84 (-0.37%).

Overall GAIN YTD: +$174,661.32 (+29.91%).

According to CNN Money our benchmark index, the S&P 500 is up +10.42% Year To Date.

Dynavax technologies had a big win today when they received approval from the advisory committee for Heplisav-B. Heplisav-B will now move on and seek formal FDA approval on or before August 10th. The FDA typically approves a drug that the AdComm Dynavax closed today at $9.25/share and is up about 80% right now in after hours trading at about $16.65. DVAX has been a solid performer for the portfolio. With our cost basis at

$4.10/share, a $16 share price will give us approximately a 290% return on the initial investment. Dynavax shares should see additional appreciation as Heplisav-B is commercialized and as their SD-101 oncology drug comes up for possible approval this summer.

Stay Invested,

Clay Baker

Disclosure: I am personally invested long in these stocks that appear in the MLH portfolio and may purchase or sell share withing the next 72 hours. I am also invested in other stocks that do not appear in the MLH portfolio: BA, BRK.B, CELG, CSCO, CTXS, CVX, DOW, DVAX, FB, IBM, NTES, NVDA, OMER, PFE, PG, RDHL, SCHW, THO, TWX, VEEV, VZ, XLNX, XOM

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.This article is not intended to offer investing advice, guarantee 100% accurate predictions, or to be interpreted as providing a personal recommendation.

Featured Posts
Recent Posts
Search By Tags
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

This material is provided for informational purposes only, as of the date hereof, and is subject to change without notice.
This material may not be suitable for all investors and is not intended to be an offer, or the solicitation of any offer, to buy or sell any securities.

© 2016 by Clay Baker all rights reserved